tbuckley/cabot-search huggingface dataset:
Abstract 16577: Plateau for Occurrence of Stent-Related Cardiac Events Beyond 3-Years After Implantation of the Sirolimus-Eluting Stent: 6-Year Follow-up of the Evastent Patients.
Authors: Gilles Barone-Rochette, Alison Foote, Jean-Louis Quesada, Gerald Vanzetto, Nicolas Danchin, Jacques Machecourt, Evastent investigators
Journal: Circulation (2010)
上消化道疾病基础知识（五）——上腹疼痛：胆囊
Authors: 黄永辉, 周丽雅
Journal: BMJ (2003)

胆结石很常见,通常并无症状产生。源于胆囊的疼痛一般为典型的胆绞痛,但各种各样的非典型性表现可使诊断变得困难。20世纪80年代手术技术受到了药物治疗和碎石术的挑战,经历了这段时间以后,现在对于有症状的胆囊结石
Abstract 14982: Impact of Health Literacy on Long-Term Outcomes in Patients with Heart Failure
Authors: Miyuki Tsuchihashi-Makaya, Shiho Matsuoka, Takahiro Kayane, Masako Koizumi, Michiyo Yamada, Akiko Okada, Miyuki Yazawa, Shintaro Kinugawa
Journal: Circulation (2014)

Introduction: Health literacy (HL) is an important concept for patient education and disease management of heart failure (HF). It has been demonstrated that HL is associated with clinical outcomes including death and readmission. Although previous research on HL has predominantly focused on functional HL (the ability to “read and write”), the World Health Organization advocates evaluation of comprehensive HL, including the ability to access information (communicative HL) and critically evaluate information (critical HL). However, the impact of these three HL components on long-term adverse outcomes in patients with HF has never been fully investigated. Methods: We conducted a prospective observational study to examine the associations between HL level and risk of death or readmission in 234 patients (mean age, 67.8 years; male, 62%). HL, including subscales of functional, communicative, and critical HL, was assessed using the HF specific HL scale, which has been reported to be valid and reliable in patients with HF. Sociodemographic, clinical, and depressive symptoms were also assessed. Mortality and hospitalization data were obtained during a 2 year follow-up (median duration, 707 days). Results: Among all patients, 19.7% exhibited a low HL score. In each subscale, 19.7%, 23.1%, and 23.9% of patients exhibited low functional, low communicative, and low critical HL, respectively. Patients with low HL were older and living alone. In multivariate Cox regression, low critical HL was independently associated with higher readmission exacerbated HF after controlling for demographic and clinical characteristics, HF severity, depressive symptoms at baseline (unadjusted rate, 23.2% vs. 9.1%; adjusted hazard ratio, 3.89 [95% CI, 1.24–12.21]; P=0.02). However, there was no association between all types of HL and mortality, and between functional and communicative HL and readmission due to HF. Conclusions: Critical HL is an independent risk factor for HF readmission in patients with HF. To improve clinical outcomes in patients with HF, effective interventions should be developed to improve patient skills for critically analyzing information and making decisions.
Abstract 3124: The Magnitude of Reclassification Indices for Individual Predictors of Global Cardiovascular Risk
Authors: Nancy R Cook, Paul M Ridker
Journal: Circulation (2008)

Methods based on risk stratification have recently been proposed to evaluate and compare predictive risk models, but their performance in clinically relevant populations has not been demonstrated, including for well-known cardiovascular risk predictors. We fit models including traditional risk factors as well as high-sensitivity C-reactive protein (hsCRP) and parental history of myocardial infarction in prospective data from 24,558 women in the Women’s Health Study who experienced 766 cardiovascular events over an average 10-year follow-up. Fit of models with and without each risk factor was evaluated using both traditional methods, including the C index and goodness-of-fit test, and newly proposed methods for reclassification, which compare predicted risk strata for two models. Reclassification calibration compares observed to predicted risk for each model within reclassified risk strata; the net reclassification improvement (NRI) estimates the net proportion of cases moving to higher vs. lower risk strata; the clinical NRI estimates the NRI among those at intermediate risk; and the integrated discrimination improvement (IDI) compares the mean difference in predicted probabilities between cases and controls for two models. For each model set, the reclassification calibration statistic showed a significant lack of fit in models excluding each of these predictors, indicating that the predicted risk did not fit that observed in reclassified strata. Values of the NRI were 20% for age, 8–11% for hemoglobin A1c in diabetics, smoking, and systolic blood pressure, and 3–5% for lipids, hsCRP, and parental history. The clinical NRI for those initially at intermediate risk was 46% for age and ranged from 9–29% for other risk factors. The IDI was less than 2% for all predictors, including age. These data demonstrate the magnitude of several newly proposed reclassification measures for well-known cardiovascular risk factors. These measures can demonstrate the potential of new models and markers to change risk strata and alter treatment decisions, and should be considered as another means to compare models and assess the accuracy of absolute risk estimates and risk strata.
Abstract 3807: Chronic Cardiac-Targeted RNA Interference for the Treatment of Severe Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy
Authors: Wolfgang Poller, Lennart Suckau, Henry Fechner, Elie Chemaly, Isaac Sipo, Lahouaria Hadri, Xiaomin Wang, Hung Ly, Yoshiaki Kawase, Jiqiu Chen, Roland Vetter, Stefan Weger, Jens Kurreck, Lifan Liang, Stefanie Krohn, Volker Erdmann, Djamel Lebeche, Heinz-Peter Schultheiss, Roger Hajjar
Journal: Circulation (2008)

RNA interference (RNAi) is a novel therapeutic strategy in cardiovascular medicine. We report on RNAi targeting phospholamban (PLB), a regulator of cardiac Ca2+ homeostasis, for the treatment of heart failure (HF). Whereas gene therapy rests on recombinant protein expression as its basic principle, RNAi therapy employs small regulatory RNAs to achieve its effect. Kinetics and toxicity of these RNAs are grossly different from those of proteins. We provide first evidence that they may achieve long-term cardiac benefit without apparent toxicity. We developed an adenoviral RNAi vector (AdV-shRNA) and a series of AAV vectors to optimize their efficacy. A novel AAV9-shPLB vector with optimized RNAi potential was chosen for HF therapy. Transaortic banding (TAB) induced HF in rats. RNAi was initiated by aortic root injection of AdV-shPLB (3x10e10 pfu/a) (Group A) or i.v. injection of AAV9-shPLB (5x10e11 vg/a) (Group B). Group A underwent short-term (1 mo.), Group B long-term therapy (3 mo.), shFGP vectors served as controls. Fig. 1 shows part of hemodynamic improvement (LVEDP, ± dp/dt, FS), hypertrophy reduction (LV/BW, LV/TL, myocyte size, collagen). Survival in group B was increased by AAV9 therapy. The study demonstrates, for the first time, high efficacy of a local cardiac RNAi therapy. Using optimized RNAi vectors and aortic root vector injection or cardiotropic AAV9 capsids to target RNAi to the heart, there was no evidence of toxicity or disturbed miRNA pathways. AdV-shPLB therapy improved HF 1 mo. after aortic root injection. A novel cardiotropic AAV9-shPLB vector mediated RNAi after simple i.v. injection and improved function, morphology, and survival in severe HF after 3 months.
Abstract 3003: Programmed Ventricular Stimulation Does Not Predict the Outcome of Patients with Arrhythmogenic Right Ventricular Cardiomyopathy (from DARVIN study)
Authors: Domenico Corrado, Loira Leoni, Mark S Link, Hugh Calkins, Thomas Wichter, Michela Bevilacqua, Cristina Basso, William J McKenna, Mark N Estes, Stefano Favale, Massimo Santini, Gianfranco Buja, Gaetano Thiene, Sabino Iliceto
Journal: Circulation (2007)

Background: The Defibrillator in Arrhythmogenic Right Ventricular Cardiomyopathy International (DARVIN) study was a multicenter investigation that enrolled patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) who received an implantable defibrillator (ICD) for either secondary or primary prevention of sudden death. Methods: In this DARVIN substudy, we examined whether programmed ventricular stimulation (PVS) is able to predict the arrhythmic risk in a large cohort of 201 ARVC patients (133 males, 68 females, aged 36 ± 12 years) who received an ICD. Implant indications were a history of cardiac arrest in 13 (6%) patients; sustained ventricular tachycardia (VT) in 82 (41%); syncope in 42 (21%); asymptomatic nonsustained VT in 40 (20%); and a family history of sudden death in 24 (12%). PVS prior to ICD implantation was carried out in 143 of 201 patients (71%). All antiarrhythmic drugs were discontinued ≥ 5 half-lives (≥ 6 weeks for amiodarone) before the study. PVS included a minimum of 2 drive cycles length and up to 3 ventricular extrastimuli while pacing from two right ventricular sites. Results: One hundred-nine patients (76%) were inducible to either sustained VT (patients 70; 64%), with a mean cycle length of 287 ± 66ms (range 220 to 410 ms), or ventricular fibrillation/flutter (VF) (patients 39; 36%). Of 109 patients who were inducible at PVS, 56 (52%) did not experience ICD therapy during a mean follow-up of 47 ± 22 months, whereas 11 of 34 (33%) noninducible patients had appropriate ICD interventions. Overall, the positive predictive value of PVS was 48%, the negative predictive value 67%, and the test accuracy 53%. The incidence of ICD discharges on VF, which in all likelihood would have been fatal in the absence of ICD therapy, did not differ between patients who were and were not inducible at PVS (26 of 109, 24% vs 7 of 34, 21%; p=0.87), regardless of clinical presentation. The type of ventricular arrhythmia inducible at PVS did not predict VF during the follow-up. Conclusions: The presence (or absence) of an inducible arrhythmia on PVS did not correlate with subsequent appropriate ICD interventions, suggesting a limited role for PVS in arrhythmic risk stratification of ARVC patient population. A negative PVS may not indicate better prognosis.
Abstract 194: Rosuvastatin Reduces Progression of Carotid Atherosclerosis within 12 Months of Treatment: The METEOR Trial
Authors: Michiel L Bots, Joel S Raichlen, Gregory W Evans, Mike K Palmer, Daniel H O’Leary, Diederick E Grobbee, John R Crouse
Journal: Circulation (2007)

Background: In several statin trials, vascular event rates for treatment groups begin to separate 1 year after commencement of treatment. For atherosclerosis progression, the temporal sequence of the effect has not been defined. We sought to determine the earliest time point at which significant differences in atherosclerosis progression rates were detectable after initiation of statin therapy using data from the METEOR trial (Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin). Methods: METEOR was a double-blind, randomized, placebo-controlled trial among 984 low risk subjects, which studied the effect of LDL lowering with 40 mg rosuvastatin on the rate of change in carotid intima media thickness (CIMT) over time. Ultrasound assessments were made at 12 carotid artery sites at baseline and every 6 months up to two years. In these analyses, the data were cut at 6 months, 1 year, and 18 months, and compared with analysis of all data at 2 years, using the same statistical method. Results: The difference in rate of maximum CIMT progression for all carotid artery sites (primary endpoint - near and far walls of the left and right common carotid artery [CCA], carotid bulb and internal carotid artery) between the rosuvastatin and placebo groups was apparent 6 months after baseline (0.0023 mm/yr and 0.0106 mm/yr, respectively p =0.36). After 12 months CIMT progression rates were significantly different between groups: 0.0032 mm/yr and 0.0133 mm/yr (p=0.049). This divergence grew with further follow-up: − 0.0009 mm/yr and 0.0131 mm/yr after 18 months (p&lt;0.0001), and − 0.0014 mm/yr and 0.0131 mm/yr after 24 months of treatment (p&lt;&lt;178&gt;0.0001). For the individual carotid artery segments, significant differences were seen at 12 months for the mean CIMT of the CCA, and at 18 months for the maximum CIMT of the bulb and the CCA. Conclusion: Aggressive LDL lowering with rosuvastatin exerts its beneficial effect on atherosclerosis during the first year of treatment, which parallels the timing of event rate reduction seen in clinical trials. These findings suggest that, in trials examining the effects of treatment on CIMT progression, a duration of 12 months may be adequate, given sufficient sample size, high precision of measurements, and treatment effect.
Abstract 12142: Catheter Ablation Outcome in AF Patients with Metabolic Syndrome
Authors: Sanghamitra Mohanty, Prasant Mohanty, Luigi Di Biase, Rong Bai, Agnes Pump, Pasquale Santangeli, David Burkhardt, Shane Bailey, Joseph Gallinghouse, Rhodney Horton, Javier Sanchez, Jason Zagrodzky, Andrea Natale
Journal: Circulation (2011)

Introduction: Different components of metabolic syndrome (MS) such as hypertension, diabetes, dyslipidemia and obesity are identified to be risk factors for atrial fibrillation (AF). This study aim...
In Vitro Reconstitution of Human B-Cell Ontogeny: From CD34+ Multipotent Progenitors to Ig-Secreting Cells
Authors: Anne-Catherine Fluckiger, Eva Sanz, Maria Garcia-Lloret, Thomas Su, Qian-Lin Hao, Roberta Kato, Shirley Quan, Antonio de la Hera, Owen N. Witte, David J. Rawlings
Journal: Blood (1998)
Cost of eradication treatment may have been overestimated
Authors: N R Waugh
Journal: BMJ (1996)

Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia Analysis is easier with spreadsheets than decision trees EDITOR,-A H Briggs et al provide an interesting perspective on the problem of what best to do for people with dyspepsia.'Clarification would be
The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells
Authors: Almut Dufner, Agnes Kisser, Sandra Niendorf, Anja Basters, Sonja Reissig, Anne Schönle, Annette Aichem, Thorsten Kurz, Andreas Schlosser, Deborah Yablonski, Marcus Groettrup, Thorsten Buch, Ari Waisman, Wolfgang W Schamel, Marco Prinz, Klaus-Peter Knobeloch
Journal: Nature Immunology (2015)
Abstract 216: A Sensitivity Analysis of Incremental Cost-Effectiveness Ratio of the Nationwide Public Access Defibrillation Program in Japan
Authors: Hiroshi Kaneko, Tetsuo Hatanaka, Aki Nagase, Seishiro Marukawa, Tetsuya Sakamoto
Journal: Circulation (2014)

Introduction: We have previously estimated the cost of and quality-adjusted life year (QALY) gained with ~200,000 AEDs placed in Japan between 2004 through 2009, and reported that the maximum likelihood estimate (MLE) of the incremental cost-effectiveness ratio (ICER) to be ~$93,980/QALY. To evaluate the robustness of the estimated ICER, we conducted a sensitivity analysis using Monte Carlo simulation. Methods: Over the study period, 3,927 patients received public access defibrillation (PAD). A control group was created by extracting, from the national database, another group of 3,927 cardiac arrest patients who did not receive PADs but otherwise matched with regard to confounders including age, sex, response time and others. The difference of the total QALY in the 2 groups yielded incremental effectiveness gained by the PAD program. The sum of the total cost for AED purchase and maintenance, cost of BLS training for first responders, and differential cost for medical care yielded the incremental cost. The value for each variable needed to calculate the incremental cost and effectiveness was randomly varied in such a way that followed the pre-defined probability density function (Table). Monte Carlo simulation was repeated 10,000 times to estimate the MLE and its 95% CI for ICER. Results: The MLE (95% CI) for the incremental cost and incremental effectiveness was ~$ 580 million (577- 583 million) and ~7,559 (6,298- 8,858) QALY, yielding ICER of $77,320 ($65,503- 92,017) /QALY (figure). Conclusions: Our estimate of the ICER seemed to be relatively robust to several assumptions. The ICER of the whole Japan PAD program seemed to be higher than desirable but still acceptable.
Abstract 15350: Multivessel Versus Target Lesion Percutaneous Coronary Intervention in Resuscitated Cardiac Arrest Patients with STEMI
Authors: Darren Mylotte, Thierry Lefevre, Helene Eltchaninoff, Nicolas Briole, Karim Tazarourte, Alain Margenet, Dominique Thebert, Jean-Francois Angellier, Yves Louvard, Marie-Claude Morice, Philippe Garot
Journal: Circulation (2011)

Objective. The role of multivessel (MV) PCI in patients with STEMI and cardiogenic shock after resuscitated cardiac arrest is unclear. We sought to compare outcomes following emergent PCI (<12 h af...
Abstract P4-04-28: Weight loss reversed the carcinogenic effect of obesity on basal-like breast cancer
Authors: Yuanyuan Qin, Sneha Sundaram, Liyang Zhao, Luma Essaid, Kirk K McNaughton, Katharine M Bendt, David B Darr, Melissa A Troester, Liza Makowski
Journal: Cancer Research (2015)

Abstract Epidemiologic studies demonstrate that obesity is associated with a subtype of breast cancer called basal-like breast cancer (BBC), which is fast proliferating and aggressive, with no targeted therapies. Using the C3(1)-TAg murine model of BBC, we have previously shown that obese adult mice displayed significantly decreased tumor latency compared to lean mice with induction of the oncogenic HGF/c-Met pathway. Reducing adiposity is predicted to lower incidence of BBC in human population studies. Thus, the objective of this study was to investigate how a diet-switch to reduce obesity affected BBC onset and early progression. C3(1)-TAg mice were placed on a control low fat diet (LFD) and remained lean, high-fat diet (HFD) to induce obesity, and a group made obese by HFD that were then switched to LFD to induce weight loss. Just two weeks after weight loss, mice in the diet switch group had weights and adiposity similar to lean mice. Weight loss caused a 51.4% decrease in adiposity (P&amp;lt;0.0001) compared to obese mice. Importantly, mice that lost weight displayed significantly delayed tumor latency (17 week) compared to obese mice on HFD (15 week), with no differences detected in tumor burden or growth. Therefore the obese microenvironment that promotes early tumor onset can be reprogrammed with weight loss and restoration of a lean phenotype. Ongoing studies are examining HGF/cMet expression by immunohistochemistry in normal mammary glands and tumors to determine the contribution of this obesity-responsive pathway. Metabolomics and RNAseq analysis will identify novel obesity-dependent pathways relevant to BBC. In conclusion, we demonstrated that loss of adiposity protected against early BBC onset. Further research will identify important biomarkers associated with obesity and weight loss that can be compared through conserved biology approaches. Citation Format: Yuanyuan Qin, Sneha Sundaram, Liyang Zhao, Luma Essaid, Kirk K McNaughton, Katharine M Bendt, David B Darr, Melissa A Troester, Liza Makowski. Weight loss reversed the carcinogenic effect of obesity on basal-like breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-04-28.
Labour and birth in water
Authors: R. Atalla, J. Weaver
Journal: BMJ (1995)

<h3>Objectives</h3> Evidence for effects of environmental contaminants on pregnancy outcomes remains inconclusive. We investigated the associations between multiple, correlated exposures and related pregnancy outcomes using Bayesian, multivariate dimension reduction, and shrinkage regression approaches to account for multiple testing and interrelatedness of exposures and outcomes. <h3>Methods</h3> We evaluated a cohort of 1322 singletons, born to 547 mothers from Greenland, 197 from Warsaw, Poland, and 588 from Kharkiv, Ukraine, who were recruited in 2002–2004 during routine antenatal care visits. Three secondary metabolites of both diethylhexyl and diisononyl phthalates (DEHP, DINP), eight perfluorinated compounds (PFCs; including PFOS and PFOA), and organochlorines (<i>p,p-</i>DDE and PCB-153) were measured and detected in 72–100% of maternal serum samples. Outcomes were preterm birth (&lt;37 weeks), birth weight, and small for gestational age (SGA; &lt;10<sup>th</sup> percentile age- and gender-specific birth weight). We analysed exposures (clustered, high dimension predictors) and continuous and dichotomous outcomes with partial least squares (PLS) regression, and sparse PLS-discriminant analysis (sPLS-DA), respectively. We compared results with elastic net penalised regression, and Bayesian stochastic search variable selection with spike-and-slab priors of (nonlinear) generalised additive models. <h3>Results</h3> While applied methods had various degrees of sparseness, we observed generally consistent associations between DEHP metabolites, several PFCs and both organochlorines, and decreased birth weight and increased risk of SGA. There was no clear evidence of associations between contaminants and preterm birth. <h3>Conclusions</h3> Findings suggest that several environmental contaminants are independently associated with impaired fetal growth. Methods which account for correlations between variables and multiple testing may better discriminate robust exposure-response associations than conventional univariate linear and logistic regression models.
Abstract 14314: miR-210 Modulates Tissue Response to Hindlimb Ischemia and the Ensuing Regeneration
Authors: Germana Zaccagnini, Eleonora Isaia, Valeria Di Stefano, Pasquale Fasanaro, Gabriele Toietta, Maurizio C Capogrossi, Fabio Martelli
Journal: Circulation (2010)

Background: MicroRNA-210 (miR-210) is a key player of endothelial cell response to hypoxia, modulating glycolysis, VEGF-driven endothelial cell migration and the ability of endothelial cells to for...